Table 1.
Summary of included trials comparing bevacizumab with interferon (Bev + IFN), sunitinib, and pazopanib to interferon alone (IFN) or one another as first-line therapy for patients with clear cell renal cell carcinoma
| Trial | Treatment arms (n) | Overall survival | Progression-free survival | Response | |||
|---|---|---|---|---|---|---|---|
| Median a | HR (95% CI) | Median a | HR (95% CI) | Percent | OR (95% CI) | ||
| Rini et al. (2008; 2013) [15, 16] | Bev + IFNb,c (n = 369) | 18.3 | 0.86 (0.73-1.01) | 8.5 | 0.71 (0.61-0.83) | 26% | 2.27 (1.51-3.42) |
| IFNc (n = 363) | 17.4 | 5.2 | 13% | ||||
| Escudier et al. (2007; 2010) [17, 18] | Bev + IFNb,c (n = 327) | 23.3 | 0.86 (0.72-1.04) | 10.2 | 0.61 (0.51-0.73) | 31%f | 3.11 (2.04-4.74) |
| IFNc (n = 322) | 21.3 | 5.4 | 13%f | ||||
| Motzer et al. (2013) [19] | Pazopanibd (n = 557) | 28.4 | 0.91 (0.76-1.08) | 8.4 | 1.05 (0.90-1.22) | 31% | 1.35 (1.03-1.75) |
| Sunitinibe (n = 553) | 29.3 | 9.5 | 25% | ||||
| Motzer et al. (2007; 2009) [14] | Sunitinibe (n = 375) | 26.4 | 0.82 (0.67-1.00) | 11 | 0.54 (0.45-0.64) | 47% | 6.33 (4.37-9.15) |
| IFNc (n = 375) | 21.8 | 5 | 12% | ||||
amonths.
bbevucizumab 10 mg/kg every 2 weeks.
cinterferon alfa 9 million units subcutaneously three times weekly.
dpazopanib 800 mg once daily.
esunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off.
fdenominator for Bev + IFN 306, denominator for IFN + Placebo 289.